Valeant goes on defensive against investor critics
It is publicly revealing for the first time the benefits that it gets from some price increases; says it has not been as dependent on drug price increases as analysts' reports claim
San Francisco
AMID an intensifying debate over drug price increases that has brought its business practices to the forefront, Valeant Pharmaceuticals International Inc fired back at critics in the investment community, publicly revealing the benefits that it gets from some price hikes for the first time.
Democrats in the US House of Representatives are pushing to subpoena the company for documents relating to drug price i…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
France's Casino supermarket chain to axe up to 3,200 jobs
Prada outshines rivals with 16% revenue lift boosted by Miu Miu
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop